Table 1.
Cohort characteristics by glioma grade.
| Variable | AMORIS1 cohort | Me-Can2 cohort | ||||
|---|---|---|---|---|---|---|
| High Grade Glioma3 (n = 476) | Total Glioma (n = 604) | No Glioma (n = 527,976) | High Grade Glioma3 (n = 164) | Total Glioma (n = 208) | No Glioma (n = 269,157) | |
| Gender (n, %) | ||||||
| Men | 301 (63%) | 390 (65%) | 283,150 (54%) | 90 (55%) | 108 (52%) | 132,767 (49%) |
| Women | 175 (37%) | 214 (35%) | 244,826 (46%) | 74 (45%) | 100 (48%) | 136,390 (51%) |
| Fasting Status (n, %) | ||||||
| Fasting | 296 (62%) | 366 (61%) | 296,850 (56%) | 164 (100%) | 208 (100%) | 269,157 (100%) |
| Non-Fasting | 180 (38%) | 238 (39%) | 231,126 (44%) | — | — | — |
| Demographic (years) | ||||||
| Median age at lab test (IQR4) | 51 (43; 58) | 50 (40; 57) | 44 (33; 54) | 50 (46; 59) | 50 (45; 59) | 44 (34; 53) |
| Median age at event or censoring5 (IQR4) | 59 (50; 65) | 57 (48; 64) | 58 (48; 68) | 58 (53; 65) | 58 (51; 65) | 55 (44; 64) |
| Median time in study (IQR4) | 7 (4; 11) | 7 (3; 11) | 15 (15; 15) | 7 (4; 10) | 7 (4; 10) | 12 (7; 15) |
| Median year lab test (IQR4) | 1988 (1986; 1992) | 1988 (1986; 1992) | 1989 (1986; 1992) | 1990 (1987; 1993) | 1990 (1988; 1993) | 1992 (1989; 1997) |
| Serum Glucose (mmol/L) | ||||||
| Median blood glucose (IQR4) | 5.0 (4.9; 5.1) | 5.0 (4.9; 5.1) | 5.0 (5.0; 5.0) | 4.9 (4.4; 5.4) | 4.9 (4.4; 5.4) | 4.9 (4.4; 5.5) |
1Apolipoprotein MOrtality RISk (AMORIS).
2Metabolic syndrome and Cancer project (Me-Can).
3Anaplastic astrocytoma and glioblastoma.
4IQR: interquartile range.
5Age at glioma diagnosis (event), death, emigration, or end of follow-up (censored); in the Me-Can cohort observations are also censored at the time of diagnosis of any cancer.